Efficacy and safety of landiolol, an ultra-short-acting beta 1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

Abstract
No abstract available
Funding Information
  • Ono Pharmaceutical

This publication has 32 references indexed in Scilit: